This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1998 Jan 10;351(9096):79-80.

doi: 10.1016/s0140-6736(05)78156-3.

Association between oral poliovaccine and Guillain-Barré syndrome?

D M Salisbury¹

Affiliations

PMID: 9439487
DOI: 10.1016/s0140-6736(05)78156-3

Association between oral poliovaccine and Guillain-Barré syndrome?

D M Salisbury. Lancet. 1998.

. 1998 Jan 10;351(9096):79-80.

doi: 10.1016/s0140-6736(05)78156-3.

Author

D M Salisbury¹

Affiliation

¹ Department of Health, London, UK.

PMID: 9439487
DOI: 10.1016/s0140-6736(05)78156-3

No abstract available

PubMed Disclaimer

Similar articles

Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré Syndrome.
Kinnunen E, Junttila O, Haukka J, Hovi T. Kinnunen E, et al. Am J Epidemiol. 1998 Jan 1;147(1):69-73. doi: 10.1093/oxfordjournals.aje.a009369. Am J Epidemiol. 1998. PMID: 9440401
Incidence of Guillain-Barré syndrome during a nationwide oral poliovirus vaccine campaign.
Kinnunen E, Färkkilä M, Hovi T, Juntunen J, Weckström P. Kinnunen E, et al. Neurology. 1989 Aug;39(8):1034-6. doi: 10.1212/wnl.39.8.1034. Neurology. 1989. PMID: 2788248
Cluster of childhood Guillain-Barré cases after an oral poliovaccine campaign.
Uhari M, Rantala H, Niemelä M. Uhari M, et al. Lancet. 1989 Aug 19;2(8660):440-1. doi: 10.1016/s0140-6736(89)90609-0. Lancet. 1989. PMID: 2569613 No abstract available.
Safety aspects of oral poliovirus vaccine campaigns.
Hovi T. Hovi T. Dev Biol Stand. 1995;84:137-44. Dev Biol Stand. 1995. PMID: 7796946 Review. No abstract available.
Rare adverse events associated with oral poliovirus vaccine in Brazil.
Friedrich F. Friedrich F. Braz J Med Biol Res. 1997 Jun;30(6):695-703. doi: 10.1590/s0100-879x1997000600001. Braz J Med Biol Res. 1997. PMID: 9292105 Review.

See all similar articles

Cited by

Emerging infectious diseases, vaccines and Guillain-Barré syndrome.
Koike H, Katsuno M. Koike H, et al. Clin Exp Neuroimmunol. 2021 Aug;12(3):165-170. doi: 10.1111/cen3.12644. Epub 2021 May 17. Clin Exp Neuroimmunol. 2021. PMID: 34230841 Free PMC article. Review.
Vaccines and Guillain-Barré syndrome.
Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Haber P, et al. Drug Saf. 2009;32(4):309-23. doi: 10.2165/00002018-200932040-00005. Drug Saf. 2009. PMID: 19388722 Review.
Toxoplasma gondii-associated Guillain-Barré syndrome in an immunocompetent patient.
Bossi P, Caumes E, Paris L, Dardé ML, Bricaire F. Bossi P, et al. J Clin Microbiol. 1998 Dec;36(12):3724-5. doi: 10.1128/JCM.36.12.3724-3725.1998. J Clin Microbiol. 1998. PMID: 9817908 Free PMC article.
Guillain-Barré syndrome: epidemiology, pathophysiology and management.
Kuwabara S. Kuwabara S. Drugs. 2004;64(6):597-610. doi: 10.2165/00003495-200464060-00003. Drugs. 2004. PMID: 15018590 Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.